vs
Side-by-side financial comparison of Climb Global Solutions, Inc. (CLMB) and PTC THERAPEUTICS, INC. (PTCT). Click either name above to swap in a different company.
Climb Global Solutions, Inc. is the larger business by last-quarter revenue ($182.4M vs $164.7M, roughly 1.1× PTC THERAPEUTICS, INC.). Climb Global Solutions, Inc. runs the higher net margin — 1.8% vs -82.0%, a 83.8% gap on every dollar of revenue. On growth, Climb Global Solutions, Inc. posted the faster year-over-year revenue change (32.1% vs -22.7%). Over the past eight quarters, Climb Global Solutions, Inc.'s revenue compounded faster (40.7% CAGR vs -11.5%).
Univar Solutions Inc. is a global chemical and ingredients distributor and provider of value-added services.
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
CLMB vs PTCT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $182.4M | $164.7M |
| Net Profit | $3.3M | $-135.0M |
| Gross Margin | 14.5% | — |
| Operating Margin | 2.1% | -43.3% |
| Net Margin | 1.8% | -82.0% |
| Revenue YoY | 32.1% | -22.7% |
| Net Profit YoY | -9.5% | -104.8% |
| EPS (diluted) | $0.18 | $-1.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $182.4M | — | ||
| Q4 25 | $193.8M | $164.7M | ||
| Q3 25 | $161.3M | $211.0M | ||
| Q2 25 | $159.3M | $178.9M | ||
| Q1 25 | $138.0M | $1.2B | ||
| Q4 24 | $161.8M | $213.2M | ||
| Q3 24 | $119.3M | $196.8M | ||
| Q2 24 | $92.1M | $186.7M |
| Q1 26 | $3.3M | — | ||
| Q4 25 | $7.0M | $-135.0M | ||
| Q3 25 | $4.7M | $15.9M | ||
| Q2 25 | $6.0M | $-64.8M | ||
| Q1 25 | $3.7M | $866.6M | ||
| Q4 24 | $7.0M | $-65.9M | ||
| Q3 24 | $5.5M | $-106.7M | ||
| Q2 24 | $3.4M | $-99.2M |
| Q1 26 | 14.5% | — | ||
| Q4 25 | 15.4% | — | ||
| Q3 25 | 15.9% | — | ||
| Q2 25 | 16.5% | — | ||
| Q1 25 | 16.9% | — | ||
| Q4 24 | 19.3% | — | ||
| Q3 24 | 20.3% | — | ||
| Q2 24 | 20.2% | — |
| Q1 26 | 2.1% | — | ||
| Q4 25 | 4.9% | -43.3% | ||
| Q3 25 | 4.3% | 1.4% | ||
| Q2 25 | 5.0% | -19.5% | ||
| Q1 25 | 3.5% | 82.5% | ||
| Q4 24 | 7.2% | -76.2% | ||
| Q3 24 | 7.1% | -27.7% | ||
| Q2 24 | 4.6% | -21.5% |
| Q1 26 | 1.8% | — | ||
| Q4 25 | 3.6% | -82.0% | ||
| Q3 25 | 2.9% | 7.5% | ||
| Q2 25 | 3.7% | -36.3% | ||
| Q1 25 | 2.7% | 73.7% | ||
| Q4 24 | 4.3% | -30.9% | ||
| Q3 24 | 4.6% | -54.2% | ||
| Q2 24 | 3.7% | -53.1% |
| Q1 26 | $0.18 | — | ||
| Q4 25 | $1.51 | $-1.63 | ||
| Q3 25 | $1.02 | $0.20 | ||
| Q2 25 | $1.30 | $-0.83 | ||
| Q1 25 | $0.81 | $10.04 | ||
| Q4 24 | $1.52 | $-0.85 | ||
| Q3 24 | $1.19 | $-1.39 | ||
| Q2 24 | $0.75 | $-1.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $41.8M | $1.9B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $118.4M | $-205.3M |
| Total Assets | $458.8M | $2.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $41.8M | — | ||
| Q4 25 | $36.6M | $1.9B | ||
| Q3 25 | $49.8M | $1.7B | ||
| Q2 25 | $28.6M | $2.0B | ||
| Q1 25 | $32.5M | $2.0B | ||
| Q4 24 | $29.8M | $1.1B | ||
| Q3 24 | $22.1M | $1.0B | ||
| Q2 24 | $48.4M | $1.1B |
| Q1 26 | $118.4M | — | ||
| Q4 25 | $116.6M | $-205.3M | ||
| Q3 25 | $109.3M | $-155.8M | ||
| Q2 25 | $105.2M | $-206.5M | ||
| Q1 25 | $95.6M | $-185.8M | ||
| Q4 24 | $90.6M | $-1.1B | ||
| Q3 24 | $87.7M | $-1.1B | ||
| Q2 24 | $79.8M | $-980.2M |
| Q1 26 | $458.8M | — | ||
| Q4 25 | $460.2M | $2.9B | ||
| Q3 25 | $376.1M | $2.6B | ||
| Q2 25 | $420.7M | $2.6B | ||
| Q1 25 | $370.1M | $2.7B | ||
| Q4 24 | $469.2M | $1.7B | ||
| Q3 24 | $371.9M | $1.8B | ||
| Q2 24 | $302.8M | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-34.3M |
| Free Cash FlowOCF − Capex | — | $-36.6M |
| FCF MarginFCF / Revenue | — | -22.3% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $702.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-11.9M | $-34.3M | ||
| Q3 25 | $22.2M | $-66.3M | ||
| Q2 25 | $-2.2M | $-58.3M | ||
| Q1 25 | $8.5M | $870.1M | ||
| Q4 24 | $16.0M | $-30.0M | ||
| Q3 24 | $-3.6M | $-77.0M | ||
| Q2 24 | $7.3M | $-71.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-36.6M | ||
| Q3 25 | — | $-69.7M | ||
| Q2 25 | — | $-59.6M | ||
| Q1 25 | — | $868.4M | ||
| Q4 24 | — | $-33.8M | ||
| Q3 24 | — | $-77.5M | ||
| Q2 24 | — | $-78.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | -22.3% | ||
| Q3 25 | — | -33.1% | ||
| Q2 25 | — | -33.3% | ||
| Q1 25 | — | 73.8% | ||
| Q4 24 | — | -15.8% | ||
| Q3 24 | — | -39.4% | ||
| Q2 24 | — | -42.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.4% | ||
| Q3 25 | — | 1.6% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 1.8% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 4.0% |
| Q1 26 | — | — | ||
| Q4 25 | -1.70× | — | ||
| Q3 25 | 4.73× | -4.17× | ||
| Q2 25 | -0.37× | — | ||
| Q1 25 | 2.30× | 1.00× | ||
| Q4 24 | 2.29× | — | ||
| Q3 24 | -0.66× | — | ||
| Q2 24 | 2.13× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
